• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies - Product Image

Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies

  • Published: March 2011
  • 84 Pages
  • GBI Research

“Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies” provides key data, information and analysis of the major trends and developments in preclinical studies and preclinical outsourcing business. The report provides a comprehensive insight into key technological developments, new approaches in developing preclinical models. The report talks about the key outsourcing business models and factors that are driving the global preclinical outsourcing market. The report also provides a detailed analysis of global preclinical market in terms of preclinical spending and preclinical outsourced value. The report also provides key alliances and acquisitions related to preclinical studies among CROs.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

Preclinical study is a critical stage in drug discovery and development. Preclinical study helps in developing a pharmacological profile of the drug and its acute toxicity. Preclinical testing involves lab and animal testing to determine if the READ MORE >

1 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Preclinical Models – Introduction 8
2.1 GBI Research Report Guidance 8
3 Preclinical Models- Market Overview 9
3.1 Drug Discovery and Development- An overview 9
3.1.1 Drug Discovery 10
3.1.2 Preclinical Study/Development 10
3.1.3 Clinical Development 11
3.2 Preclinical Studies- An overview 12
3.3 Preclinical Study Design and Planning 12
3.3.1 Preclinical Study - Strategic Planning 12
3.3.2 Key Considerations during Preclinical Study Design 13
3.4 Preclinical Studies- In-house 14
3.5 Preclinical Studies- Outsourced 14
3.5.1 Independent Contracting 14
3.5.2 Complete Outsourcing 14
3.6 Role of a CRO 15
3.7 Regulatory Aspects of Preclinical Studies 16
3.7.1 The Principles of Good Laboratory Practice 16
3.7.2 NIH and AAALAC 16
4 Preclinical Models- Preclinical Outsourcing Models 17
4.1 Reasons for Outsourcing Preclinical Studies 17
4.1.1 Optimizing Cost 18
4.1.2 Achieving Speed and Flexibility 18
4.1.3 Access to Specialty Resources, Technological Advancements, Equipment and Facilities 18
4.1.4 Minimizing the Risks Associated with the Early Stages of the Drug Discovery Development Process 18
4.1.5 Focus on Core Competencies 19
4.2 Preclinical Outsourcing Process 19
4.2.1 Steps Involved In Outsourcing a Preclinical Project 19
4.2.2 Criteria for Selecting a Contract Research Organization 21
4.2.3 Preclinical Outsourcing Business Models 22
4.3 Outsourcing Trends 23
4.3.1 Strategic Partnerships and R&D collaborations with Pharmaceutical Companies 23
4.3.2 Capacity Concerns 24
4.3.3 Innovative Management of Outsourcing Projects 24
4.3.4 Strategic Shift in Funding and Payment Patterns 24
4.3.5 Emergence of “One-Stop-Shop CROs” and “Boutique Providers” 24
4.4 Case Studies 25
4.4.1 Early Stage Preclinical Project 25
4.4.2 Long Term Partnerships with Drug Discovery and Preclinical Service Providers 26
5 Preclinical Models- Technology Landscape 27
5.1 Current System 27
5.1.1 Overview 27
5.1.2 Key Technologies 27
5.1.3 In-Vitro ADMET Screening Models 28
5.1.4 In-vivo ADMET Screening Models 29
5.1.5 In-silico ADMET Screening models 30
5.2 Trends in Technology Models 31
5.2.1 Recent Technology Developments 31
5.2.2 New Approaches 33
5.3 Case Studies-Preclinical Models (Technological Developments) 35
5.3.1 Apredica’s Customized In-vitro ADMET Screening Assays 35
5.3.2 AVEO Pharmaceuticals’ Breakthrough with Transgenic Mouse Model for Human Breast Cancer 36
5.3.3 In-vitro Models for Dermal Corrosion / Irritation and Eye Irritation by Charles River 37
5.3.4 Preclinical Models of Hepatocellular Carcinoma and Biomarker Strategy by Pfizer 38
5.3.5 SimuGen’s HT-Stream, a Preclinical Toxicogenomics System/Model 39
5.3.6 A Validated Physiologically Based Mathematical Model of Pathogenesis in the Non-Obese Diabetic Mouse by Entelos 39
5.3.7 Simulation Modeling to Treat Spinal Cord Injuries by Novartis 40
5.3.8 Recent Development in Preclinical Imaging by Caliper Life Sciences 41
6 Preclinical Models- Market Characterization 42
6.1 Global Spending on Prehuman/Preclinical Studies 42
6.2 Preclinical Spending by Geography 43
6.3 Global Preclinical Outsourcing Market 44
6.4 Key Market Drivers and Restraints 45
6.4.1 Market Drivers 45
6.4.2 Key Restraints 46
7 Preclinical Models- Geographical Analysis 47
7.1 Germany 47
7.2 The UK 48
7.3 Switzerland 49
7.4 Italy 50
7.5 France 51
7.6 Belgium 52
7.7 Denmark 53
7.8 Spain 54
7.9 Sweden 55
7.10 The US 56
8 Preclinical Models- Company Profiling 57
8.1 Charles River Laboratories International, Inc. 57
8.1.1 Business Overview 57
8.1.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 58
8.2 Cyprotex Discovery Ltd. 59
8.2.1 Business Overview 60
8.2.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 60
8.3 Shanghai ChemPartner 61
8.3.1 Business Overview 61
8.3.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 61
8.4 Covance, Inc. 62
8.4.1 Business Overview 62
8.4.2 Recent M&A Deals and Alliances in Preclinical Research 63
8.5 PPD, Inc. 64
8.5.1 Business Overview 64
8.5.2 Recent M&A Deals and Alliances in Preclinical Research 64
8.6 Ricerca Biosciences, LLC 65
8.6.1 Business Overview 65
8.6.2 Recent M&A Deals and Strategic Alliances 65
8.7 Caliper Life Sciences 66
8.7.1 Business Overview 66
8.7.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 67
8.8 GVK BIO 68
8.8.1 Business Overview 68
8.8.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 69
8.9 MPI Research 70
8.9.1 Business Overview 70
8.9.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 70
8.10 MDS 71
8.10.1 Business Overview 71
8.11 MD Biosciences 72
8.11.1 Business Overview 72
8.11.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 72
8.12 Aptuit 73
8.12.1 Business Overview 73
8.12.2 Recent M&A Deals and Strategic Alliances in Preclinical Research 73
8.13 ITR Canada 74
8.13.1 Business Overview 74
8.14 Advinus Therapeutics 75
8.14.1 Business Overview 75
8.14.2 Recent M&A Deals and Strategic Alliances 76
8.15 Jubilant Biosys 77
8.15.1 Business Overview 77
8.15.2 Major M&A Deals and Strategic Alliances 78
8.16 AMRI 79
8.16.1 Business Overview 79
8.16.2 Recent Deals in Preclinical Research 79
9 Preclinical Models- Appendix 80
9.1 Market Definitions 80
9.2 List of Abbreviations 81
9.3 Research Methodology 82
9.3.1 Coverage 82
9.3.2 Secondary Research 82
9.3.3 Primary Research 83
9.3.4 Expert Panel Validation 83
9.4 Contact Us 83
9.5 Disclaimer 83
9.6 Sources 84

1.1 List of Tables
Table 1: Preclinical Models, Global Prehuman/Preclinical Spending, ($m), 2009-2016 42
Table 2: Preclinical Models, Preclinical Spending by Geography, 2009 43
Table 3: Preclinical Models, Global Preclinical Outsourcing Market, ($m), 2009-2016 44
Table 4: Preclinical Models, Germany, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 47
Table 5: Preclinical Models, The UK, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 48
Table 6: Preclinical Models, Switzerland, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 49
Table 7: Preclinical Models, Italy, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 50
Table 8: Preclinical Models, France, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 51
Table 9: Preclinical Models, Belgium, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 52
Table 10: Preclinical Models, Denmark, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 53
Table 11: Preclinical Models, Spain, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 54
Table 12: Preclinical Models, Sweden, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 55
Table 13: Preclinical Models, The US, Total R&D, Preclinical R&D & Outsourced Preclinical R&D Spending, $m, 2009 56

1.2 List of Figures
Figure 1: Drug Discovery and Development Process 9
Figure 2: Preclinical Models, Preclinical Services Offered by a CRO 15
Figure 3: Preclinical Models, Reasons for Outsourcing Preclinical Studies 17
Figure 4: Preclinical Models, Key Factors Considered for Selecting a CRO for Preclinical Outsourcing 21
Figure 5: Preclinical Models, Preclinical Outsourcing Models & In-house Preclinical R&D 22
Figure 6: Preclinical Models, Preclinical ADMET Studies- Current System 27
Figure 7: Preclinical Models, New Approaches for Conducting Preclinical Studies 33
Figure 8: Preclinical Models, Global Preclinical Spending, ($m), 2009-2016 42
Figure 9: Preclinical Models, Preclinical Spending by Geography, 2009 43
Figure 10: Preclinical Models, Global Preclinical Outsourcing Market, ($m), 2009-2016 44
Figure 11: Preclinical Models, Key Market Drivers and Restraints for Preclinical Outsourcing 45
Figure 12:Preclinical Models, Germany, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 47
Figure 13: Preclinical Models, The UK, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 48
Figure 14: Preclinical Models, Switzerland, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 49
Figure 15: Preclinical Models, Italy, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 50
Figure 16:Preclinical Models, France, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 51
Figure 17: Preclinical Models, Belgium, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 52
Figure 18: Preclinical Models, Denmark, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 53
Figure 19:Preclinical Models, Spain, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 54
Figure 20:Preclinical Models, Sweden, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 55
Figure 21: Preclinical Models, The US, Total R&D, Preclinical R&D and Outsourced Preclinical R&D Spending, $m, 2009 56
Figure 22:Preclinical Models, Charles River Laboratories International, Inc - Corporate Profile 57
Figure 23: Preclinical Models, Cyprotex Discovery Ltd. - Corporate Profile 59
Figure 24: Preclinical Models, Shanghai ChemPartner- Corporate Profile 61
Figure 25: Preclinical Models, Covance, Inc - Corporate Profile 62
Figure 26: Preclinical Models, PPD, Inc - Corporate Profile 64
Figure 27: Preclinical Models, Ricerca Biosciences, LLC - Corporate Profile 65
Figure 28: Preclinical Models, Caliper Life Sciences, Inc - Corporate Profile 66
Figure 29: Preclinical Models, GVK BIO- Corporate Profile 68
Figure 30: Preclinical Models, MPI Research - Corporate Profile 70
Figure 31: Preclinical Models, MDS, Inc - Corporate Profile 71
Figure 32: Preclinical Models, MD Biosciences- Corporate Profile 72
Figure 33: Preclinical Models, Aptuit, Inc. - Corporate Profile 73
Figure 34: Preclinical Models, ITR Canada, Inc - Corporate Profile 74
Figure 35: Preclinical Models, Advinus Therapeutics, Inc - Corporate Profile 75
Figure 36: Preclinical Models, Jubilant Biosys, Inc - Corporate Profile 77
Figure 37: Preclinical Models, Albany Molecular Research, Inc (AMRI)- Corporate Profile 79

“Preclinical Models - Preclinical CROs will Continue to Improve the Quality and Accuracy of Data for Targeted Therapies” provides key data, information and analysis of the major trends and developments in preclinical studies and preclinical outsourcing business. The report provides a comprehensive insight into key technological developments, new approaches in developing preclinical models. The report talks about the key outsourcing business models and factors that are driving the global preclinical outsourcing market. The report also provides a detailed analysis of global preclinical market in terms of preclinical spending and preclinical outsourced value. The report also provides key alliances and acquisitions related to preclinical studies among CROs.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

New Approaches for Conducting Preclinical Studies Improve the Quality of Preclinical Data and Speed up the Preclinical R&D Process

Pharmaceutical/biotechnology companies partner with CROs, academic and government institutions to design and develop new approaches and models for conducting preclinical research. Advancements in molecular biology/genetic engineering and computational methods help researchers to tackle various problems in the preclinical research.

Simulation and system biology models improve the quality and reliability of preclinical data. Novel models by several pharmaceutical companies and contract research organizations proved to be effective in reducing preclinical process cycle time.

Contract Research Organizations Offer a Wide Range of Preclinical In-vitro and In-vivo Services to Enhance their Service Portfolio

Preclinical studies make use of systems or models such as in-vitro, in-vivo and in-silico models, for conducting a wide range of preclinical research and development studies. Absorption, distribution, metabolism, excretion and toxicology (ADMET) studies are conducted initially to investigate and correlate the test compound’s absorption, distribution, metabolism, excretion, and toxicology profile in preclinical systems with humans. There is considerable number of contract research organizations (CROs), providing a wide range of preclinical design and testing services. Some of the top CROs such as Charles River Laboratories, Covance and Cyprotex offer both customized and standardized preclinical services and models to their clients (pharmaceutical and biotechnology companies) and they continue to grow with strategic acquisitions and partnerships. Furthermore CROs from Asian countries (especially from India and China) such as Jubilant Biosys, Advinus and Shanghai ChemPartner also emerging up with their customized preclinical offerings.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos